Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • JUNE 2021 Issue has been successfully launched on 1 June 2021.



Ishita Ajith, Krithika Balakrishnan and Shivani Vinay Mistry


Seasonal Allergic Conjunctivitis (SAC) also called hay fever is a type of common allergy (Hypersensitivity type 1 reaction regulated by IgE) to various airborne environmental allergens like pollens, grass, weed, animal dander etc. The clinical symptoms include ocular itching, discharge, tearing or watering of the eyes and lid edema. Mast cells play the main role in the pathophysiology as they are responsible for releasing histamines and prostaglandins as a response to allergens. Treatments usually include antihistamines and non-steroidal anti-inflammatory drugs (NSAIDs) which inhibit prostaglandin synthesis, such as ketorolac. A new topical drug, olopatadine, has been shown to have a dual action, in terms of both mast cell degranulation inhibition and histamine receptor blockage. The aim of the study was done to test the effectiveness of the two drugs with different mechanism of action on the clinical signs and symptoms of SAC. A randomized placebo-controlled study was conducted among 40 patients suffering with SAC who had a history of the disease and weren‟t on medication for 4 weeks prior to the study. The patients were divided into 2 groups; the first group was given olopatadine in one eye and placebo in the other twice daily and the second group was given ketorolac in one eye and placebo in the other for four times a day. Clinical signs and symptoms were evaluated at baseline, and at 30 mins and 2,7 and 15 days. In group 1, there was a significant improvement in eyes treated with olopatadine compared with those receiving placebo.Similarly, eyes treated with ketorolac showed significant reductions in signs and symptoms compared with those receiving placebo. Both olopatadine and ketorolac ophthalmic solutions were found to be effective in alleviating the clinical signs and symptoms of SAC compared to placebo. However, olopatadine reduces ocular itching significantly more than ketorolac.

Keywords: .

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More